U.S. markets open in 3 hours 23 minutes
  • S&P Futures

    4,418.25
    -19.75 (-0.45%)
     
  • Dow Futures

    34,532.00
    -112.00 (-0.32%)
     
  • Nasdaq Futures

    15,216.00
    -87.50 (-0.57%)
     
  • Russell 2000 Futures

    2,243.40
    -11.80 (-0.52%)
     
  • Crude Oil

    73.36
    +0.06 (+0.08%)
     
  • Gold

    1,754.20
    +4.40 (+0.25%)
     
  • Silver

    22.65
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1736
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • Vix

    19.92
    -0.95 (-4.55%)
     
  • GBP/USD

    1.3702
    -0.0019 (-0.14%)
     
  • USD/JPY

    110.3980
    +0.0970 (+0.09%)
     
  • BTC-USD

    42,564.65
    -1,482.18 (-3.37%)
     
  • CMC Crypto 200

    1,052.38
    -56.54 (-5.10%)
     
  • FTSE 100

    7,054.62
    -23.73 (-0.34%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2021 adjusted earnings per share of $3.11, which beat the Zacks Consensus Estimate of $2.69. Earnings rose 19% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.

Revenues of $1.79 billion, which surpassed the Zacks Consensus Estimate of $1.71 billion, comprised fully of CF product revenues. Total product revenues rose 18% year over year, primarily driven by the rapid uptake of Trikafta in Europe (marketed as Kaftrio) and continued growth in the United States. Product revenues rose 4% year over year to $1.26 billion in the United States and surged 71% to $536 million outside the country.

Shares of Vertex have lost 15.2% so far this year against the industry’s increase of 0.3%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

CF Franchise Sales Performance

Vertex’s newest drug, Trikafta, a triple combination therapy, generated sales worth $1.26 billion, up 36.8% year over year, driven by high level of treatment penetration in the United States as well as strong launches in international markets.

In June 2021, the FDA approved Trikafta to treat CF in children aged six to 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

Kaftrio was approved in Europe in August 2020. Following the nod, the drug saw substantial uptake across all European countries. The company has now secured reimbursement agreements in more than 15 countries, most importantly the large markets of Germany and the United Kingdom.

Symdeko/Symkevi registered sales of $134 million in the quarter, down 22.1% year over year.

Kalydeco recorded sales of $183 million in the quarter, reflecting a 9.8% decrease year over year. Orkambi generated sales of $221 million in the reported quarter, down 4.7%. Sales of Kalydeco, Symdeko/ Symkevi and Orkambi were hurt by patients switching to Trikafta.

Costs Rise

Adjusted operating income rose 18% to $1.03 billion in the quarter, driven by higher revenues and cost control.

Adjusted research and development (R&D) expenses rose 19.3% to $383 million due to expansion of CF and non-CF pipeline.

Adjusted selling, general and administrative (SG&A) expenses increased 5.4% to $154 million in the reported quarter due to investments made to support the expansion of the CF business.

2021 Guidance

Vertex revised its product revenue guidance for 2021 upward owing to strong business performance and reimbursement agreements for Kaftrio in Europe, along with approval for younger age groups in the United States.

The company now expects revenues from CF products in the range of $7.2-$7.4 billion compared with the previous range of $6.7-$6.9 billion. The midpoint of the guidance reflects approximately 18% growth over the previous guidance.

Combined adjusted R&D and SG&A expenses for 2021 are expected in the band of $2.25 to $2.30 billion. Adjusted tax rate is expected in the range of 21-22%. All unchanged from the previous guidance.

Pipeline Update

While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing early-stage portfolio in five additional diseases beyond CF.

Per the company, apart from CF, Vertex’s most advanced program is CTX001, a CRISPR/Cas9-based gene editing therapy, which is being co-developed in partnership with CRISPR Therapeutics CRSP for two devastating diseases — sickle cell disease (“SCD”) and transfusion-dependent beta thalassemia (“TDT”). In June 2021, the companies announced positive new data from a phase I/II study evaluating CTX001 in patients with TDT as well as those with SCD, with a follow-up of at least three months. The gene-editing therapy candidate demonstrated a consistent and sustained response to treatment in the given patient population.

In April 2021, Vertex increased its investment in the collaboration. Under the amended deal, Vertex will lead the global development and future commercialization of CTX001.

Enrolment is underway in a phase II study on VX-147, its first oral small molecule medicine in APOL1-mediated focal segmental glomerulosclerosis. Data from the study is expected in the second half of 2021.

Earlier this month, Vertex initiated a proof-of-concept phase II study for its investigational NaV1.8 inhibitor candidate, VX-548, to treat acute pain following bunionectomy surgery. Data from this study is anticipated in first-quarter 2022.

VX-880 is Vertex’s first of the two investigational programs for the transplant of functional islets into patients. VX-880 is for the transplantation of islet cells alone, using immunosuppression to protect the implanted cells. The second program will involve the implantation of the islet cells inside an immunoprotective device. A phase I/II study on VX-880 in the islet cells alone program, is currently ongoing for the treatment of type I diabetes (T1D). Initial data from the same is expected in 2022.

In June 2021, Vertex decided to stop the late-stage development of its investigational oral small molecule corrector, VX-864, which was being evaluated for the treatment of alpha-1 antitrypsin deficiency (“AATD”). The decision was taken despite a phase II study on the candidate in AATD, an inherited condition that raises risk of lung and liver disease, achieving its primary endpoint.

The company believed that the magnitude of treatment effect observed in the study is unlikely to lead to any substantial clinical benefit.

Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise

Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise


Vertex Pharmaceuticals Incorporated price-consensus-eps-surprise-chart | Vertex Pharmaceuticals Incorporated Quote

Zacks Rank & Other Stocks to Consider

Vertex currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector include Bio-Techne Corporation TECH and Repligen Corporation RGEN, both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Bio-Techne’s earnings estimates have been revised 2.3% upward for 2021 and 4.2% upward for 2022 over the past 60 days. The stock has rallied 52.1% year to date.

Repligen’s earnings estimates have been revised 2.3% upward for 2021 and 3.5% upward for 2022 over the past 60 days. The stock has increased 25.8% year to date.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

Repligen Corporation (RGEN) : Free Stock Analysis Report

BioTechne Corp (TECH) : Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research